Nutcracker Therapeutics is an early-stage company that develops and manufactures RNA-based treatments for various diseases. This information is self-described.

Nutcracker Therapeutics

Nutcracker Therapeutics | 4,043 followers on LinkedIn. Nutcracker Therapeutics is developing mRNA therapeutics and a novel GMP manufacturing platform. | Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform’s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications.

From R to D, too

Babak Sanii

Human Resources Executive | Culture Builder | Leadership Coach

Angela Peters

Carolyn Carrillo

Co-Founder and Chief Executive Officer, Simplify Genomics

Travis Lacey

We're thrilled to be in Boston for this year's PODD conference! Colin McKinlay will be giving a talk on our peptoid-based Nutshell® delivery vehicles.

Our pipeline has gotten a new look! Our therapeutic programs demonstrate the versatility of mRNA as a therapeutic and in vaccines: NTX-250, which targets the HPV infection that causes cervical cancer and dysplasia; NTX-470, which targets metastatic castration-resistant prostate cancer; and NTX-472, which targets B cell autoimmune and lymphoma diseases.

It's been a busy couple of months! Over the past quarter our team presented on the advancement of mRNA therapeutics, our Nutshell® Delivery Vehicles, our Nutcracker® Manufacturing Unit, antigen receptor design for solid tumors, and using machine learning to optimize drug design. Here's to a busy last quarter of the year!

Ray L. will be attending the 16th Drug Discovery Strategic Summit next week in San Francisco. We'd love to see you there!

Gunasekaran (Guna) Kannan shares his thoughts on how mRNA can be used to overcome the development challenges in designing protein therapeutics. Thank you Guna and The Medicine Maker for making this article possible! Read the article here: https://lnkd.in/e4EJdnE9

We'll be at the AI in Drug Discovery Xchange in San Francisco tomorrow! Evan McCartney-Melstad will be leading a roundtable on how machine learning can be used to optimize structure-based drug design.

We're excited that Christian Moreno will be participating in a Cell & Gene panel titled: "From Bottleneck to Breakthrough: Reimagining the mRNA Therapeutics Supply Chain," tomorrow starting at 11AM ET! Tune in here: https://lnkd.in/eRtF-gFF

We'll be at the Antibody Therapeutics Xchange in San Francisco next week on Monday the 23rd! Gunasekaran (Guna) Kannan will be leading a late breaking roundtable discussion on "current challenges in design of bispecific / chimeric antigen receptors for solid tumours," focusing on target identification and specificity, tumor microenvironment barriers, and off-target toxicity and safety concerns. We'd love to see you there!

We'll be at the mRNA Process Development & Manufacturing Summit this week in Boston! Babak Sanii will be giving a talk titled: "Scalable Microfluidic Factories to Manufacture mRNA Personalized Cancer Vaccines." We'd love to see you there!

We can't believe it's September already! Over the last several months, our team members presented on our engineered transmembrane immunomodulator, ENG-LIGHT; our mRNA therapeutic for prostate cancer, NTX-470; our latest therapeutic program for B-cell autoimmune and lymphoma diseases, NTX-472; new methods of delivery for oncology therapeutics; our CodonCracker™ software; and analytical control strategies for the production of quality mRNA.

Domain Not Resolving

Google Maps

CrUX Dataset

CrUX Top 50m

Google Maps Embed

Chief Business Officer

Geoff Nosrati

Chief Financial Officer

James Zhu

Vice President, Regulatory Affairs

Christine Wu

Vice President and Head of Non-Clinical and Clinical Development

Swami Murugappan

Director, BioChip Manufacturing Engineering and Supply Chain

Abdullah Taheri

Director & Head - Quality Control

Abhita Malavia

Director of Recruiting

Andy Infante

Associate Director, Engineering R&D

Associate Director, Quality Planner | Driving Operational Excellence

Carolina C.

Business Management

Chris Rae

Jeff Bird

Michael F. Bigham

Igor Khandros

Co-Founder and CEO

Benjamin Eldridge

Co-Founder and CTO

Robert Schott

Chief Medical Officer

Chief Human Resources Officer

Western US Late Stage Companies With More Than 100 Employees

West Coast Startups Founded in 2018

United States Companies With More Than 100 Employees (Top 10K)

West Coast Companies With More Than 100 Employees (Top 10K)

Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, thereby enabling healthcare companies to produce complex multimodal therapeutics at point of care.

Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips.

Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2018.

ARCH Venture Partners

Series C - Nutcracker Therapeutics

Series B - Nutcracker Therapeutics

Venture Round - Nutcracker Therapeutics

Emeryville

California

United States

North America

Nutcracker Therapeutics' Research Partner, the University of California, San Francisco, Presents Foundational Prostate ...

Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology ...

Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the ...

Nutcracker Therapeutics on LinkedIn: We are so excited that our very own Oreanna Thomas will be participating…

news impact assignment basic	general
public peers	general	Nov 6, 2024 11:18 PM	90b20ef4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 11:18 PM	2bd4716c
crunchbase trigger	general	Nov 6, 2024 11:18 PM	63300b64
crunchbase profile	general	Nov 7, 2024 6:30 PM	22a7c87c
li profile	general	Nov 6, 2024 11:18 PM	a2d58478
translate crunchbase fundingrounds	general	Nov 7, 2024 7:12 PM	59163cdf
peers	general	Nov 6, 2024 11:18 PM	a9040f03
news basic	general	Nov 6, 2024 11:18 PM	edd39dad
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

NUTC

COM:NUTCRACKERX

Nutcracker Therapeutics